

TABLE 86 Summary results for the sensitivity analyses for mixed-treatment comparison (HR, 95% CI) for OS comparing chemotherapy vs chemotherapy in population 1: population with squamous disease

Reference treatment vs comparator	Mixed-treatment comparison A (n = 16), HR (95% CI)	Mixed-treatment comparison B (n = 18), HR (95% CI)	Mixed-treatment comparison C (n = 18), HR (95% CI)	Mixed-treatment comparison D (n = 17), HR (95% CI)	Mixed-treatment comparison E (n = 17), HR (95% CI)
GEM + PLAT vs VNB + PLAT ^{43,45,49,50,54,55,57,58}	1.09 (1 to 1.19)	1.09 (1 to 1.19)	1.07 (0.98 to 1.17)	1.09 (0.99 to 1.19)	1.09 (0.99 to 1.19)
GEM + PLAT vs PAX + PLAT ^{43,46,47,56,57,60}	1.05 (0.96 to 1.15)	1.06 (0.96 to 1.16)	1.05 (0.96 to 1.15)	1.05 (0.96 to 1.15)	1.05 (0.96 to 1.15)
GEM + PLAT vs DOC + PLAT ⁴⁷	0.99 (0.86 to 1.13)	0.99 (0.86 to 1.14)	1.07 (0.93 to 1.23)	0.99 (0.86 to 1.14)	0.99 (0.87 to 1.13)
VNB + PLAT vs PAX + PLAT ^{43,48,51,57}	0.96 (0.86 to 1.08)	0.97 (0.86 to 1.08)	0.98 (0.87 to 1.1)	0.96 (0.86 to 1.08)	0.96 (0.86 to 1.08)
VNB + PLAT vs DOC + PLAT ^{44,52,53,59}	0.91 (0.79 to 1.04)	0.9 (0.79 to 1.03)	1 (0.87 to 1.14)	0.91 (0.8 to 1.03)	0.91 (0.81 to 1.03)
PAX + PLAT vs DOC + PLAT ⁴⁷	0.94 (0.8 to 1.11)	0.93 (0.8 to 1.1)	1.02 (0.87 to 1.2)	0.95 (0.81 to 1.11)	0.95 (0.82 to 1.11)

A HR > 1 favours the reference treatment and a HR < 1 favours the comparator treatment.